Bozkurt, Ibrahim HalilSefik, ErtugrulCelik, SerdarYesilova, ArdaKoras, OmerDegirmenci, Tansu2024-09-182024-09-1820220937-34621433-3023https://doi.org/10.1007/s00192-022-05250-1https://hdl.handle.net/20.500.12483/11544Introduction and hypothesis We aimed to compare on-demand and continuous use of fesoterodine 4 mg concerning efficacy and adverse effects. Methods A total of 100 patients who were diagnosed with non-neurogenic overactive bladder (OAB) syndrome were included in the study. All patients were evaluated with MMSE, ICIQ-SF, SEAPI quality of health and OAB-V8 questionnaires, at the beginning, 1st month and 4th month. Fesoterodine 4 mg was started for treatment. At the end of the 1st month, patients who obtained benefit from the treatment were 1:1 randomized into two groups. In group 1, fesoterodine 4 mg was given 1 x 1 in a standard manner whereas in group 2 patients took the pills on demand. Both groups were evaluated for efficacy and adverse events at 4 months. Results Final analyses included 69 patients. At 4-month follow-up, OAB-V8 scores were significantly improved compared to 1 month in both groups. Again at h months, no difference was detected between the two groups for MMSE, ICIQ-SF and SEAPI scores. In continuous usage group, 4th month MMSE scores were significantly lower than 1st month scores. At 4 months, dry mouth and constipation were lower in the on-demand group compared to continuous usage group. Conclusions Compared to standard continuous usage, on-demand usage of fesoterodine showed similar efficacy with fewer adverse events.eninfo:eu-repo/semantics/closedAccessOveractive bladderFesoterodineOn-demand therapyContinuous useAntimuscarinicsArticle3382127213210.1007/s00192-022-05250-1356662892-s2.0-85131435242Q2WOS:000806672200001Q4